Intuitive Surgical (ISRG) files Form 144 to sell 336 restricted shares
Rhea-AI Filing Summary
Intuitive Surgical (ISRG) filed a Form 144 reporting a proposed sale of 336 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 09/03/2025. The filing lists an aggregate market value of $157,956.96 and shows 358,476,506 shares outstanding. The shares to be sold were originally issued as restricted stock: 102 shares acquired 04/27/2023 and 234 shares acquired 04/25/2024; payment is listed as Not Applicable. The filing reports no securities sold during the past three months. Several administrative fields (filer CIK/CCC and issuer contact details) are not populated in the provided text.
Positive
- Filing documents compliance with Rule 144 and publicly discloses the proposed insider sale
- Acquisition history for the shares is provided (dates and amounts), improving traceability
Negative
- None.
Insights
TL;DR: Small insider sale filing; amount is negligible relative to total shares outstanding and is primarily a compliance disclosure.
The Form 144 notifies the market of a proposed sale of 336 restricted shares with an aggregate value of $157,956.96, scheduled via a Morgan Stanley broker on NASDAQ. Given the issuer's outstanding share count of 358,476,506, the position represents an immaterial fraction of equity outstanding. There are no reported sales in the prior three months. From an analytical standpoint, this filing is routine disclosure under Rule 144 and does not, by itself, signal a material change to the company’s capital structure or investor base.
TL;DR: The filing reflects standard insider compliance; documentation of restricted stock origins is appropriate and complete in the tables provided.
The notice records that the shares were acquired as restricted stock from the issuer on two dates and specifies the broker and planned sale date, which aligns with regulatory expectations for transparency about insider dispositions. The absence of reported sales in the prior three months and the clear listing of acquisition dates and amounts support traceability. Some issuer and filer contact fields are blank in the extract, which limits administrative completeness but does not alter the substantive disclosure about the securities to be sold.
FAQ
What does the ISRG Form 144 report?
How were the shares being sold acquired according to the filing?
Does the Form 144 show any securities sold in the past three months for this account?
What is the issuer’s outstanding share count listed in the filing?
Which broker is named to execute the sale in the Form 144?